6.67
price up icon3.09%   0.20
after-market Handel nachbörslich: 6.60 -0.07 -1.05%
loading
Schlusskurs vom Vortag:
$6.47
Offen:
$6.46
24-Stunden-Volumen:
1.30M
Relative Volume:
1.03
Marktkapitalisierung:
$577.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-3.0737
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+8.81%
1M Leistung:
+14.02%
6M Leistung:
-15.14%
1J Leistung:
-67.86%
1-Tages-Spanne:
Value
$6.3919
$6.675
1-Wochen-Bereich:
Value
$6.135
$6.695
52-Wochen-Spanne:
Value
$5.41
$21.60

Kura Oncology Inc Stock (KURA) Company Profile

Name
Firmenname
Kura Oncology Inc
Name
Telefon
(858) 500-8800
Name
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Name
Mitarbeiter
192
Name
Twitter
@kuraoncology
Name
Nächster Verdiensttermin
2025-02-21
Name
Neueste SEC-Einreichungen
Name
KURA's Discussions on Twitter

Vergleichen Sie KURA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KURA
Kura Oncology Inc
6.67 530.70M 0 -168.09M -138.01M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-06 Herabstufung BTIG Research Buy → Neutral
2024-10-24 Eingeleitet UBS Buy
2024-10-14 Herabstufung Stifel Buy → Hold
2023-12-22 Eingeleitet Mizuho Buy
2023-08-11 Eingeleitet BofA Securities Buy
2023-07-27 Eingeleitet Scotiabank Sector Perform
2023-05-17 Eingeleitet BTIG Research Buy
2023-01-31 Eingeleitet Stifel Buy
2022-07-12 Eingeleitet Cantor Fitzgerald Overweight
2022-02-15 Eingeleitet Jefferies Buy
2021-05-05 Fortgesetzt Credit Suisse Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-12-07 Bestätigt H.C. Wainwright Buy
2020-12-03 Eingeleitet Stifel Buy
2020-11-05 Herabstufung Piper Sandler Overweight → Neutral
2020-07-07 Eingeleitet Credit Suisse Outperform
2020-05-05 Eingeleitet Barclays Overweight
2019-07-18 Eingeleitet Deutsche Bank Buy
2018-11-09 Eingeleitet Piper Jaffray Overweight
2018-08-01 Eingeleitet H.C. Wainwright Buy
2016-10-13 Fortgesetzt Leerink Partners Outperform
2016-01-22 Eingeleitet JMP Securities Mkt Outperform
2015-12-30 Eingeleitet Oppenheimer Outperform
2015-12-16 Eingeleitet Citigroup Buy
Alle ansehen

Kura Oncology Inc Aktie (KURA) Neueste Nachrichten

pulisher
Jul 22, 2025

Kura Oncology Inc. Stock Analysis and ForecastExplosive earnings growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Kura Oncology Inc. stockTriple-digit returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Kura Oncology Inc. stock priceBreakneck growth rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Kura Oncology Inc. a good long term investmentConsistently high returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jul 18, 2025
pulisher
Jul 16, 2025

Why Kura Oncology Inc. stock attracts strong analyst attentionFree AI-Driven Trading Strategies - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

How Kura Oncology Inc. stock performs during market volatilityFree Access to Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Kura Oncology Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt? - simplywall.st

Jul 14, 2025
pulisher
Jul 10, 2025

Wealth Enhancement Advisory Services LLC Takes $139,000 Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Jul 10, 2025
pulisher
Jul 03, 2025

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 03, 2025
pulisher
Jul 03, 2025

Kura Oncology shares rise 3.34% after-hours following inducement grants to new employees. - AInvest

Jul 03, 2025
pulisher
Jul 02, 2025

Kura Oncology's Ziftomenib: A Near-Term FDA Catalyst and a Paradigm Shift for AML Patients - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

Kura Oncology Partners with Kyowa Kirin for Ziftomenib - TipRanks

Jul 01, 2025
pulisher
Jul 01, 2025

Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US - Investing.com

Jul 01, 2025
pulisher
Jul 01, 2025

Kura Oncology and Kyowa Kirin enter agreement to co-promote leukemia drug in US By Investing.com - Investing.com South Africa

Jul 01, 2025
pulisher
Jun 29, 2025

Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 3000E Value Index - MarketScreener

Jun 29, 2025
pulisher
Jun 27, 2025

Kura Oncology (NASDAQ:KURA) Given Overweight Rating at Cantor Fitzgerald - Defense World

Jun 27, 2025
pulisher
Jun 26, 2025

KURA: Cantor Fitzgerald Reiterates Overweight Rating | KURA Stoc - GuruFocus

Jun 26, 2025
pulisher
Jun 22, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Rhumbline Advisers - Defense World

Jun 22, 2025
pulisher
Jun 20, 2025

KURA: Wedbush Reiterates 'Outperform' Rating with $36 Price Target | KURA Stock News - GuruFocus

Jun 20, 2025
pulisher
Jun 18, 2025

Transcript : Kura Oncology, Inc.Special Call - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN

Jun 17, 2025
pulisher
Jun 15, 2025

Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Australia

Jun 14, 2025
pulisher
Jun 13, 2025

Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 12, 2025

KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Kura Oncology stock rises on leukemia drug data (KURA:NASDAQ) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Is The Options Market Predicting A Spike In Kura Oncology Stock? - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Kura Oncology and Kyowa Kirin Report Positive Updated Combinatio - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment By Investing.com - Investing.com Canada

Jun 12, 2025

Finanzdaten der Kura Oncology Inc-Aktie (KURA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):